Sintilimab - Eli Lilly and Company/Innovent Biologics
Alternative Names: Anti-PD-1 antibody - Eli Lilly and Company/Innovent Biologics; IBI 308; LY-3342901; Sintilimab injection; Sintilimab injection - Eli Lilly and Company/Innovent Biologics; Tyvyt; Xindili DankangLatest Information Update: 17 Jul 2024
At a glance
- Originator Adimab; Innovent Biologics
- Developer Chinese Academy of Medical Sciences; Eli Lilly and Company; Fujian Cancer Hospital; HUTCHMED; Innovent Biologics; Jiangsu Hengrui Medicine Co.; Jiangsu Provincial Peoples Hospital; Laekna Therapeutics; Peking University; Shanghai Jiaotong University School of Medicine; Sun Yat-Sen University; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gastric cancer; Hodgkin's disease; Liver cancer; Non-small cell lung cancer; Oesophageal cancer
- Phase III Acral lentiginous melanoma; Colorectal cancer; Nasopharyngeal cancer
- Phase II/III Renal cell carcinoma
- Phase II Cancer; Cervical cancer; Extranodal NK-T-cell lymphoma; Neuroendocrine tumours; Small cell lung cancer
- Phase I/II Solid tumours
- Phase I Lung cancer; Lymphoma
Most Recent Events
- 17 Jul 2024 Efficacy and adverse event data from the phase Ib/II FRUSICA-1 trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 21 Jun 2024 Innovent Biologics completes a phase I trial in Liver cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT04401813)
- 31 May 2024 Efficacy and adverse events data from the phase III trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)